


# Journal Pre-proof

Sex-based Differences in TB Treatment Compliance: A Mediating Factor for Sputum Conversion Among Newly Diagnosed Pulmonary TB Patients in Chennai, South India

Yuvaraj Krishnamoorthy, C Selvaraja, Dhanajayan Govindan



PII: S2405-8440(24)07216-5

DOI: <https://doi.org/10.1016/j.heliyon.2024.e31185>

Reference: HLY 31185

To appear in: *HELIYON*

Received Date: 25 November 2023

Revised Date: 9 May 2024

Accepted Date: 12 May 2024

Please cite this article as: Sex-based Differences in TB Treatment Compliance: A Mediating Factor for Sputum Conversion Among Newly Diagnosed Pulmonary TB Patients in Chennai, South India, *HELIYON*, <https://doi.org/10.1016/j.heliyon.2024.e31185>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Ltd.

**Sex-based Differences in TB Treatment Compliance: A Mediating Factor for Sputum Conversion Among Newly Diagnosed Pulmonary TB Patients in Chennai, South India**

**Yuvaraj Krishnamoorthy<sup>1,2</sup>, C Selvaraja<sup>3</sup>, Dhanajayan Govindan<sup>4</sup>**

<sup>1</sup>Assistant Professor, Department of Community Medicine, ESIC Medical College and Hospital, KK Nagar, Chennai 600078, Phone: +91 9551892665

<sup>2</sup>Head, Evidence Synthesis Unit, Partnership for Research, Opportunity, Planning, Upskilling and Leadership (PROPUL) Evidence, Chennai – 600099, India

Email id: [yuvi.1130@gmail.com](mailto:yuvi.1130@gmail.com)

Alternate Email id: [yuvaraj@propulevidence.org](mailto:yuvaraj@propulevidence.org)

<sup>3</sup>Assistant Professor, Department of Pulmonary Medicine, ESIC Medical College and Hospital, KK Nagar, Chennai 600078, Phone: +91 9791709505;

Email id: [ljcljcljc17@gmail.com](mailto:ljcljcljc17@gmail.com);

<sup>4</sup>Assistant Professor, Department of Community Medicine, ESIC Medical College and Hospital, KK Nagar, Chennai 600078, Phone: +91 7904422741

Email: [gdhanajayanj@gmail.com](mailto:gdhanajayanj@gmail.com)

**Corresponding Author:**

Yuvaraj Krishnamoorthy

Assistant Professor, Department of Community Medicine, ESIC Medical College and Hospital, KK Nagar, Chennai 600078,

Head, Evidence Synthesis Unit, Partnership for Research, Opportunity, Planning, Upskilling and Leadership (PROPUL) Evidence, Chennai – 600099, India

Phone: +91 9551892665 Email: [yuvi.1130@gmail.com](mailto:yuvi.1130@gmail.com)

**Ethical approval:** This study was approved by Institutional Ethics Committee of ESIC Medical College & Hospital (IEC number: IEC/2022/2/50)

**Acknowledgement:** Nil

**Conflict of interest:** None declared

**Funding:** The work was supported by grant from Tuberculosis Association of India (TAI) under short term research projects financial assistance scheme (2022-23). The grant was awarded to Dr. Yuvaraj Krishnamoorthy.

**Author Contributions:**

**Yuvaraj Krishnamoorthy:** Conceptualization; Methodology; Software; Validation; Formal analysis; Investigation; Resources; Data Curation; Project administration; Funding acquisition; Visualization; Supervision; Writing - Original Draft; Writing - Review & Editing

**C Selvaraja:** Conceptualization; Methodology; Software; Validation; Investigation; Resources; Project administration; Visualization; Supervision; Writing - Review & Editing

**Dhanajayan Govindan:** Methodology; Software; Validation; Investigation; Resources; Project administration; Visualization; Supervision; Writing - Review & Editing

**Abstract**

**Background:** Tuberculosis (TB) remains a global health concern, particularly in India, which carries a significant portion of the global burden. The role of sex as a determinant of health is increasingly recognized, impacting various aspects of TB, including treatment compliance and outcomes. This study aimed to determine the mediating role of treatment compliance in the relationship between sex and sputum conversion in newly diagnosed pulmonary TB patients in Chennai, South India.

**Methods:** We conducted a retrospective cohort study among patients newly diagnosed for TB at ESIC Medical College & PGIMSIR between April 2020 and April 2022. A causal mediation analysis was performed to identify the direct and indirect effects of sex on sputum conversion

via the mediator, treatment compliance. We employed logistic regression models and the "paramed" package for the analysis, with bootstrapping technique for examining the significance of indirect and direct effects.

**Results:** The Marginal Total Effect (MTE) suggested that females were more likely to have sputum positivity compared to males (OR: 6.77;  $p=0.003$ ). Direct effect of being female increased the odds of sputum positivity at the end of the intensive phase (OR: 3.42;  $p=0.03$ ). The indirect effect of being female via treatment compliance significantly increased the odds of sputum positivity at the end of the intensive phase (OR: 1.98;  $p=0.03$ ).

**Conclusion:** The study provides evidence that treatment compliance significantly mediates the relationship between sex and sputum conversion in TB patients, highlighting the necessity to consider gendered dimensions of health in TB control strategies.

**Keywords:** Mediation Analysis, Medication Adherence, Sputum Positivity, Tuberculosis, Compliance

## Introduction

Tuberculosis (TB) remains a significant global public health concern, despite considerable advancements in disease control and prevention strategies.<sup>(1)</sup> Global TB report 2022 has reported that around 1.6 million deaths have occurred due to TB, an increase from 1.5 million in 2020 and 1.4 million in 2019 (taking it back to the 2017 levels).<sup>(2)</sup> This has happened despite the reduction in the incidence of TB from 7.1 million in 2019 to 5.8 million in 2020.<sup>(3)</sup> This indicates that the number of individuals with undetected and untreated TB has expanded, leading initially to a rise in TB-related fatalities and heightened transmission of the infection within communities.<sup>(4)</sup>

India, as a major contributor to the global TB burden, has been striving to improve prevention, diagnosis, and treatment services through the Revised National Tuberculosis Control Program

(RNTCP) and the National TB Elimination Programme (NTEP).<sup>(5)</sup> However, numerous challenges persist, including inadequate funding, limited access to health resources, stigmatization, poverty, and non-compliance.<sup>(6)</sup> The initiation and completion of anti-TB treatment is crucial in controlling the spread of the disease and enhancing patient survival. However, non-compliance to TB treatment poses a significant challenge to these goals.<sup>(7)</sup> Treatment non-compliance can lead to the perpetuation of disease transmission, extended illness, increased mortality, and the emergence of drug-resistant TB strains.<sup>(8)</sup> Therefore, understanding the variables influencing treatment compliance is paramount to effectively combat TB.

Sex, as a biological and social determinant of health, has been increasingly recognized as influencing various aspects of TB, including vulnerability to infection, disease progression, and treatment outcomes.<sup>(9,10)</sup> While biological differences between sexes may account for some disparities, social factors, often intertwined with gender roles and expectations, also play a significant role. These may manifest as differential access to health services, health-seeking behaviours, social stigma, and financial independence, among others.<sup>(11)</sup> The impact of sex on treatment compliance, and in turn, on sputum conversion—a key indicator of treatment success—is complex and multi-faceted.

Under NTEP, all new cases of drug-sensitive tuberculosis are treated with daily fixed-dose combinations of first-line antituberculosis drugs in appropriate weight bands. The intensive phase consists of eight weeks of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide. In the continuation phase, Isoniazid, Rifampicin and Ethambutol are continued for another 16 weeks. Sputum smear microscopy and/or culture is done at the end of the intensive phase and continuation phase to assess the prognosis of the disease.<sup>(12)</sup>

Sputum conversion, the transition from a positive to a negative sputum smear or culture, is a critical milestone in TB treatment. It typically indicates a reduction in infectivity and a positive

response to therapy. Non-compliance to treatment, however, could disrupt this process, prolonging the infectious period and jeopardizing the treatment's success.<sup>(13)</sup> Hence, exploring this relationship could offer valuable insights to inform TB control strategies that consider the gendered dimensions of health.

Causal mediation analysis, a powerful statistical tool, enables us to dissect the direct and indirect effects of an exposure (in this case, sex) on an outcome (sputum conversion), via a mediator (treatment compliance).<sup>(14)</sup> This approach facilitates a deeper understanding of the relationships between these variables and helps uncover potential intervention points.

This study, therefore, contributes to the burgeoning literature on the interplay between sex, treatment compliance, and sputum conversion in TB patients. It emphasizes the need to recognize and address the diverse needs and experiences of males and females in TB care and control. By exploring these complex relationships in the specific context of Chennai, this study also adds to the evidence base required to design and implement more tailored and effective TB interventions in India and other similar settings. Hence, this study was done to determine the mediating role of treatment compliance in the relationship between sex and sputum conversion at the end of the intensive phase in newly diagnosed pulmonary TB patients in Chennai, South India.

## **Methods**

### ***Study setting and participants***

This study was conducted as a part of a large-scale retrospective cohort study amongst patients newly diagnosed with TB at ESIC Medical College & PGIMSIR between April 1, 2020 and April, 2022 were enrolled. Patients aged 6 years and above with newly diagnosed pulmonary TB were included. Patients with previous history of TB or drug-resistant TB were excluded.

### ***Study procedure***

Ethical approval was obtained from the Institutional Ethics Committee (IEC) of ESIC Medical College, Chennai. Tuberculosis treatment details namely sociodemographic details, co-morbidities, addiction history, diagnosis, treatment and follow-up history were retrieved from NIKSHAY portal. NIKSHAY, India's web-based tuberculosis (TB) surveillance system, serves as a comprehensive platform for the electronic management of TB patients, enabling real-time case notification, treatment monitoring, and outcome tracking. Additionally, a pretested semi-structured questionnaire was utilized to collect any missing information from participants via phone interviews. Informed consent was obtained from adult participants ( $\geq 18$  years) or parents of children (6-17 years). Data collection occurred during May and June 2023.

A total of 531 TB patients (231 females, 43.7%) were newly diagnosed at ESIC Medical College & PGIMSIR between April 1, 2020, and April 2022. Of the 531, 237 (68 females, 28.7%) were identified as pulmonary TB cases. All these patients were diagnosed with tuberculosis by sputum acid-fast bacilli smear and 236 patients (except one female) were initiated on anti-tuberculosis treatment at ESIC Medical College and Hospital. Incomplete information and missing entries in the NIKSHAY portal were collected from the patients through phone interviews. After excluding those with missing contact details or who did not respond, 213 patients (57 females, 26.8%) were enrolled in our study.

### **Operational definitions**

**New case:** A TB patient who has never had treatment for TB or has taken anti-TB drugs for less than a month

### **Treatment Compliance**

The data used in this study was gathered from the patients' treatment cards available on NIKSHAY portal upon the completion of the intensive phase. It displays the information about daily intake of anti-tuberculosis medications through dots-99 technology in the form of colour coded bands. Green indicates consumption of medicine and red indicates skipping of

medication. This information was noted down from the portal by research assistants. Patients who consistently took their medication (>80 % of the days) throughout the entire intensive phase were deemed to have demonstrated good compliance to the tuberculosis treatment regimen.

### **Sputum Conversion**

Sputum conversion is the achievement of a negative result, indicating the absence of *Mycobacterium tuberculosis*, in sputum smear examination using acid-fast bacilli (AFB) staining or culture following tuberculosis treatment initiation. Information about treatment compliance and sputum conversion was obtained from NIKSHAY portal and from phone call interviews.

### **Sputum Positivity**

Sputum Positivity is the presence of *Mycobacterium tuberculosis* in the sputum sample of the patient demonstrated by sputum AFB staining or culture after TB treatment initiation.

### **Statistical analysis**

We have performed a mediation analysis in STATA v14.0 using the logistic regression (to account for binary mediator and outcome variables) models that take mediator into account when estimating controlled direct (CDE), natural direct (NDE) and indirect effect (NIE). The NDE reports the exposure-outcome link without the inclusion of a mediator variable, while the NIE reflects the portion of the exposure-outcome relationship that includes mediator.

The equations fitted with the logistic regression (binary mediator and dependent variable) are as follows:<sup>(15)</sup>

$$Y = i_1 + cX \quad \dots \text{(Equation 1)}$$

$$M = i_2 + aX \quad \dots \text{(Equation 2)}$$

$$Y = i_3 + c'X + bM \quad \dots \text{(Equation 3)}$$



In **Equation 1**, 'Y' denotes the dependent variable (sputum positivity), while 'c' symbolizes the gradient of the independent variable (sex). In the **Equation 2**, 'M' stands for mediator variable (compliance to treatment), and 'a' indicates gradient of the independent variable (sex). In the **Equation 3**, 'Y' stands for dependent variable (sputum positivity), 'c' signifies the gradient of the independent variable (sex), and 'b' designates the gradient of the mediator variable (compliance to treatment). In all these equations, 'i' is representative of intercept.

The odds ratio (OR) for the NIE and NDE are calculated using the **Equation 4 & 5**<sup>14</sup>:

$$IndirecteffectOR(NIE) = \frac{(1 + \exp(i_2))}{(1 + \exp(i_2 + a))} + \frac{(1 + \exp(b + i_2 + a))}{(1 + \exp(b + i_2))} \dots (Equation 4)$$

$$DirecteffectOR(NDE) = \exp(c') \dots (Equation 5)$$

In this context, 'i2' denotes intercept derived from equation two, 'b' signifies the coefficient 'b' from equation three, 'a' designates a coefficient from equation two, and 'c' stands for the coefficient 'c' derived from equation three.

We determined the relative scale of mediated effect using two metrics: the proportion mediated (PM) and the mediated to non-mediated ratio. The formula for calculation are given in **Equation 6 & 7**.<sup>(16)</sup>

$$PM = \frac{NIE}{TotalEffect} \dots (Equation 6)$$

$$Ratio\ of\ mediated\ to\ non - mediated\ effect = \frac{NIE}{NDE} \dots (Equation 7)$$

To ensure compatibility with the odds ratios calculated for the direct and indirect effects, we transformed these effects to their natural logarithms prior to the calculation of the PM effect and the ratio of mediated to non-mediated effect. The logarithm transformation was

implemented because the odds ratios, which are a measure of effect size in our logistic regression analysis, are multiplicative. By taking natural logarithms, we are able to convert these multiplicative odds ratios into additive log-odds units, making it possible to meaningfully add and subtract these quantities for the purpose of our calculations. The formula are given in **Equation 8 & 9** as follows:

$$PM = \frac{\ln(NIE)}{\ln(TotalEffect)} \dots (Equation 8)$$

$$Ratio\ of\ mediated\ to\ non - mediated\ effect = \frac{\ln(NIE)}{\ln(NDE)} \dots (Equation 9)$$

Figure 1 illustrates the assumed relationship among the variables. The arrow's orientation signifies the impact direction. We proposed that the sex exerts both direct and indirect influences (through treatment compliance) on sputum positivity at completion of intensive phase.

To evaluate the association between exposure variable (sex) and mediator variable (treatment compliance), between the mediator (treatment compliance) and outcome variable (sputum positivity), and between the exposure (sex) and outcome variable (sputum positivity), we utilized the Baron and Kenny method with logistic regression models.<sup>(17)</sup>

After ensuring the primary assumptions were met, we conducted a mediation analysis using the "paramed" package.<sup>(18)</sup> To assess the significance of the indirect and direct impacts, we implemented a bootstrapping method (with 500 iterations) coupled with the bootstrapped bias-corrected Confidence Intervals.

## Results

Of the total 213 participants, 9 (4.2) died and 11 (5.16) were lost to follow up. Characteristics of the participants are given in **Table-1**. Among females, 2 (3.50) died and 4 (7.01) were lost

to follow-up. In terms of sputum conversion at the end of the intensive phase, among the 213 pulmonary TB patients, 44 (20.7%) remained positive for *Mycobacterium tuberculosis*, indicating unsuccessful sputum conversion and ongoing infection. Sputum positivity at the end of the Intensive phase was 15.4 % among males and 35.1 % among females ( $p=0.002$ ). Of the 44 sputum-positive cases, 19 (43.2) achieved sputum conversion at the end of the continuation phase, 4 (9.1) died, 7 (15.9) were lost to follow-up and 10 (22.7) were labelled as emerging resistance. Among females 9 (45.0) achieved sputum conversion at the end of the continuation phase, 2 (10.0) died, 5 (25.0) were lost to follow-up and 3 (15.0) were labelled as emerging resistance.

Non-compliance to Tb treatment was found to be higher among females (14, 24.6%) compared to males (19, 12.2%) with an odds ratio of OR: 2.35; 95% CI: 1.09-5.08 ( $p=0.03$ ). Sputum positivity was found to be higher among treatment-non-compliant (31, 93.9%) compared to treatment-compliant patients (13, 7.2%) with an odds ratio of 199.11; 95% CI: 42.80-926.24 ( $p<0.001$ ). Since both the basic assumptions were satisfied, mediation analysis was performed to study the direct and indirect effects of sex on sputum positivity (**Table-2**).

**Table 3** provides the results of causal mediation analysis with non-compliance to TB treatment compliance as mediator between sex and sputum conversion in the cohort of newly diagnosed pulmonary TB patients. Marginal Total Effect MTE indicated that females were significantly more likely to have sputum positivity at the end of the intensive phase compared to males (OR: 6.77; 95% CI: 1.93-23.73;  $p=0.003$ ). The analysis found that the direct effect of being female not mediated by treatment compliance increased the odds of sputum positivity at the end of the intensive phase (OR: 3.42; 95% CI: 1.15-10.22;  $p=0.03$ ). The indirect effect of being female via treatment non-compliance significantly increased the odds of sputum positivity at the end of the intensive phase (OR: 1.98; 95% CI: 1.08-3.62;  $p=0.03$ ).

Our analysis involved the application of natural logarithms (ln) to convert the Odds Ratios (OR) of the Direct and Indirect Effects into a more suitable format for our computations. Specifically, the OR for the Direct Effect (3.42) was transformed to a ln value of 1.23, while the OR for the Indirect Effect (1.98) corresponded to a ln value of 0.68.

Following these transformations, we calculated the Proportional Mediated (PM) effect, which represented the portion of the total effect of sex on sputum positivity mediated by non-compliance to TB treatment. The PM was found to be 0.36, implying that approximately 36% influence of sex on sputum positivity was mediated by variations in treatment compliance between males and females. We also calculated the ratio of the mediated (Indirect) effect to the non-mediated (Direct) effect. This ratio yielded a value of 0.55. This indicates that for every unit increase in the non-mediated effect of being female on sputum positivity, there is a 0.55-fold increase in the mediated effect through non-compliance to TB treatment.

## Discussion

Our study revealed a significant disparity in the sex ratio among notified pulmonary TB cases, with the gap gradually narrowing across all forms of tuberculosis. This observation aligns with existing literature suggesting gender-specific variations in TB presentation and diagnosis. Studies have consistently shown a higher prevalence of microbiologically confirmed pulmonary TB among men, while women are more prone to clinically diagnosed pulmonary TB and extrapulmonary TB forms.<sup>(19-23)</sup> Women may present with nonspecific symptoms, potentially contributing to delays in diagnosis.<sup>(19,23-24)</sup> Additionally, in Asia, younger women are disproportionately affected by extrapulmonary TB and female genital TB, further underscoring the importance of considering gender in TB surveillance and management.<sup>(19,25)</sup> The convergence of our findings with established patterns in TB epidemiology enhances the accuracy and generalizability of our data.

The causal mediation analysis presented in this study reveals profound insights into the multifaceted interplay between sex, treatment compliance, and sputum positivity among newly diagnosed pulmonary tuberculosis (TB) patients in Chennai, South India. Through careful examination of both direct and indirect effects, the findings spotlight the intersectionality of sex and treatment compliance in shaping interim TB outcomes.

Firstly, the marginal total effect indicates that females were significantly more likely to have sputum positivity at the end of the intensive treatment phase when compared to males. This finding aligns with existing literature which has underscored sex-based disparities in interim TB treatment outcomes.<sup>(26-28)</sup> The reasons for such disparities are possibly multifactorial in nature, shaped by a combination of biological, social, and health system-related determinants. Biologically, sex-related differences in immune responses could influence susceptibility to TB infection, disease progression, and response to therapy.<sup>(11)</sup> From a socio-cultural perspective, females may face unique challenges such as gender-related stigma, socio-economic constraints, limited decision-making power, and healthcare access barriers that can affect their health-seeking behaviors and treatment compliance.<sup>(11)</sup> Additionally, health systems may not be adequately gender-responsive, potentially leading to the provision of suboptimal care for female patients.<sup>(29)</sup>

Upon disentangling the total effect, the study identifies significant direct and indirect effects of sex on sputum positivity. The direct effect highlights an intrinsic link between sex and sputum positivity, independent of treatment compliance. This suggests that being female alone increases the odds of sputum positivity at the end of the intensive phase, hinting at the other social factors like difference in addiction rates between sexes, biological and genetic factors that may affect interim treatment outcomes. Although the mechanisms behind this are not fully understood, possibilities could include influence of sex hormones on the immune responses or

pharmacokinetics of the anti-tubercular drugs necessitating further research to corroborate these hypotheses.<sup>(30)</sup>

Simultaneously, the indirect effect identifies the influence of sex on sputum positivity mediated by treatment compliance. Females were found to be significantly more likely to be non-compliant with TB treatment, which, in turn, increased their likelihood of sputum positivity at the end of the intensive phase. This finding underscores the salient role of treatment compliance in determining TB treatment outcomes and throws light on the need to address gender-based barriers to medication compliance.

Treatment non-compliance is a well-known barrier to TB control, with far-reaching consequences such as prolonged disease transmission, increased disease severity, and the emergence of drug-resistant TB.<sup>(7,8)</sup> For females, treatment non-compliance could be driven by various factors, such as limited access to healthcare services, economic constraints, social stigma associated with TB, lack of autonomy, fear of discrimination, inadequate knowledge about the disease, and side effects of the medication.<sup>(31)</sup>

Contrary to conventional understanding, which attributed poor Tb treatment outcomes among women to barriers in access and social factors, our study uncovered a different reality. While acknowledging the impact of such barriers, we found that treatment compliance emerged as a pivotal factor influencing TB outcomes, particularly among women. Moreover, our findings suggest that addressing compliance issues, in addition to improving access may have a more pronounced impact on improving TB outcomes among women than mitigating other social determinants. Sensitizing the health care providers and TB treatment supporters such as DOTS providers and Senior Treatment supervisors on gender-responsive TB care would improve treatment compliance and treatment outcomes.<sup>(19)</sup>

Moreover, this also confirms the substantial relationship between treatment compliance and sputum positivity, where non-compliant patients had significantly higher odds of having sputum positivity.<sup>(32-33)</sup> This association reinforces the global emphasis on ensuring treatment compliance for successful TB control and validates the myriad interventions aimed at promoting compliance, such as patient-centred care, DOTS-99, treatment literacy, and social support.<sup>(34)</sup>

This study has the following set of limitations. Firstly, as the study was conducted in Chennai, South India, the findings might not be generalizable to other regions with differing socio-cultural contexts or health system characteristics. Secondly, there may be potential unmeasured confounding variables such as socio-economic status, educational level, or genetic factors that were not accounted for in the analysis, which could influence both treatment compliance and interim TB outcomes. Finally, while this study examined the mediating role of treatment compliance in the relationship between sex and sputum positivity, it did not explore other potential mediators such as access to healthcare, stigma, or gender norms. This multi-dimensional aspect necessitates further investigation to provide a comprehensive understanding of the observed disparities.

This study has important implications for public health policy. This study contributes significantly to the growing body of evidence demonstrating sex-based disparities in TB outcomes. Identifying the pathways through which sex influences sputum conversion, mediated by treatment compliance, offers valuable insights to guide gender-responsive TB control strategies. It underscores the necessity of tackling the complex barriers to treatment compliance, particularly among females, to improve TB outcomes. Addressing these challenges will require concerted, multi-sectoral efforts that engage not only health systems but also communities and individuals to foster an enabling environment that promotes treatment compliance and ultimately, successful TB control.

However, the study also serves as a reminder that our understanding of the intricate interplay between sex, treatment compliance, and sputum positivity remains incomplete. More comprehensive research is needed to fully understand the underlying mechanisms and to tailor interventions effectively. As the world strives towards the goal of ending TB, we must recognize and address these gender-based disparities to ensure that no one is left behind in the fight against this devastating disease.

### **Conclusion:**

Overall, the study findings provide evidence that treatment compliance partially mediates the relationship between sex and sputum positivity at the end of the intensive phase. While females have a direct higher risk of sputum positivity, part of their increased risk is also explained by lower treatment compliance. Interventions targeting treatment compliance, particularly among female patients, may help to reduce sputum positivity and improve overall TB treatment outcomes.

**Data availability statement:** Data will be made available upon reasonable request.

### **References:**

1. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017.
2. Bagcchi S. WHO's Global Tuberculosis Report 2022. *Lancet Microbe* 2023;4(1):e20. doi: 10.1016/S2666-5247(22)00359-7
3. Chakaya J, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB. *Int J Infect Dis* 2022;124:S26-9. doi:10.1016/j.ijid.2022.03.011



4. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts. *Int J Infect Dis* 2021; 113:S7-12. doi: 10.1016/j.ijid.2021.02.107.
5. Khanna A, Saha R, Ahmad N. National TB elimination programme - What has changed. *Indian J Med Microbiol* 2023;42:103-7. doi: 10.1016/j.ijmmb.2022.10.008.
6. Thakur G, Thakur S, Thakur H. Status and challenges for tuberculosis control in India - Stakeholders' perspective. *Indian J Tuberc* 2021;68(3):334-9. doi:10.1016/j.ijtb.2020.10.001
7. Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. *Int J Tuberc Lung Dis* 2011;15:871–85.
8. Tesfahuneygn G, Medhin G, Legesse M. Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. *BMC Res Notes* 2015;8:503. doi: 10.1186/s13104-015-1452-x.
9. Central TB Division. Ministry of Health and Family Welfare. National Framework for a Gender-Responsive Approach to TB in India. [Internet] [cited 23 Jun 2023]. Available from:  
[https://tbcindia.gov.in/WriteReadData/1892s/388838054811%20NTEP%20Gender%20Responsive%20Framework\\_311219.pdf](https://tbcindia.gov.in/WriteReadData/1892s/388838054811%20NTEP%20Gender%20Responsive%20Framework_311219.pdf)
10. Krishnamoorthy Y, Ezhumalai K, Murali S, Rajaa S, Majella MG, Sarkar S, et al. Development of prognostic scoring system for predicting 1-year mortality among pulmonary tuberculosis patients in South India. *J Public Health (Oxf)* 2023;45(2):e184-95. doi: 10.1093/pubmed/fdac087
11. Onifade, D.A., Bayer, A.M., Montoya, R. et al. Gender-related factors influencing tuberculosis control in shantytowns: a qualitative study. *BMC Public Health* 2010; 10:381. <https://doi.org/10.1186/1471-2458-10-381>

12. TOG-Chapter 4-Treatment of TB Part 1: Ministry of Health and Family Welfare [Internet]. [cited 2023 Oct 13]. Available from: <https://tbcindia.gov.in/showfile.php?lid=3219>
13. Kayigamba FR, Bakker MI, Mugisha V, De Naeyer L, Gasana M, Cobelens F, et al. Adherence to tuberculosis treatment, sputum smear conversion and mortality: a retrospective cohort study in 48 Rwandan clinics. *PLoS One* 2013;8(9):e73501. doi: 10.1371/journal.pone.0073501
14. VanderWeele TJ. Mediation Analysis: A Practitioner's Guide. *Annu Rev Public Health* 2016;37:17-32. doi: 10.1146/annurev-publhealth-032315-021402
15. Rijnhart JJM, Twisk JWR, Eekhout I, Heymans MW. Comparison of logistic-regression based methods for simple mediation analysis with a dichotomous outcome variable. *BMC Med Res Methodol* 2019;19(1):19
16. Introduction to Statistical Mediation Analysis [Internet]. Routledge & CRC Press. [cited 2023 Oct 13]. Available from: <https://www.routledge.com/Introduction-to-Statistical-Mediation-Analysis/MacKinnon/p/book/9780805864298>
17. Baron RM, Kenny DA: The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol* 1986;51(6):1173-82.
18. PARAMED: Stata module to perform causal mediation analysis using parametric regression models. In [<https://ideas.repec.org/c/boc/bocode/s457581.html>]
19. Central Tuberculosis Division. New Delhi: National Framework for a Gender-responsive Approach to TB in India ; Ministry of Health with Family Welfare; 2019 [updated 2024 March 20; cited 2024 April 13] Available from: <https://tbcindia.gov.in/index1.php?page=2&ipp=10&lang=1&level=1&sublinkid=4571&lid=3176>

20. Balasubramanian R, Garg R, Santha T, Gopi PG, Subramani R, Chandrasekaran V, Thomas A, Rajeswari R, Anandakrishnan S, Perumal M, Niruparani C, Sudha G, Jaggarajamma K, Frieden TR, Narayanan PR. Gender disparities in tuberculosis: report from a rural DOTS programme in south India. *Int J Tuberc Lung Dis*. 2004;8(3):323-332.
21. Dandona R, Dandona L, Mishra A, Dhingra S, Venkatagopalakrishna K, Chauhan LS. Utilization of and barriers to public sector tuberculosis services in India. *Natl Med J India*. 2004;17(6):292-299.
22. Mukherjee A, Saha I, Sarkar A, Chowdhury R. Gender differences in notification rates, clinical forms and treatment outcome of tuberculosis patients under the RNTCP. *Lung India*. 2012;29(2):120. <https://doi.org/10.4103/0970-2113.95302>
23. Weiss M, Christian Auer DS, Abdallah Abouihia JK, M Shaheed Jawahar FK, N L Arias. Gender and tuberculosis: cross-site analysis and implications of a multi-country study in Bangladesh, India, Malawi, and Colombia [Internet]. WHO. Available from: <http://www.who.int/tdr/publications/tdr-researchpublications/gender-tb-multicountry-study/en/> (accessed 2.22.18).
24. Long NH, Diwan VK, Winkvist A. Difference in symptoms suggesting pulmonary tuberculosis among men and women. *J Clin Epidemiol*. 2002;55(2):115-120.
25. Sharma JB, Sharma E, Sharma S, Dharmendra S. Female genital tuberculosis: Revisited. *Indian J Med Res*. 2018;148:71. [https://doi.org/10.4103/ijmr.IJMR\\_648\\_18](https://doi.org/10.4103/ijmr.IJMR_648_18).
26. Stanikzai MH, Bairwa M, Wasiq AW, Gupta SD, Akbari K. Factors Influencing Sputum Smear Conversion among Smear Positive Pulmonary Tuberculosis Patients in Kandahar City, Afghanistan. *J Clin Diagn Res* 2019;13(10):18-21
27. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and

- relationship to treatment outcome. *Ann Intern Med* 2006;144(9):650-9. doi: 10.7326/0003-4819-144-9-200605020-00008. PMID: 16670134.
28. Iqbal Z, Khan MA, Aziz A, Nasir SM. Time for culture conversion and its associated factors in multidrug-resistant tuberculosis patients at a tertiary level hospital in Peshawar, Pakistan. *Pak J Med Sci* 2022;38(4Part-II):1009-15. doi: 10.12669/pjms.38.4.5058.
  29. Hay K, McDougal L, Percival V, Henry S, Klugman J, Wurie H, et al. Disrupting gender norms in health systems: making the case for change. *Lancet* 2019 Jun 22; 393(10190): 2535-49. doi: 10.1016/S0140-6736(19)30648-8.
  30. Taneja V. Sex Hormones Determine Immune Response. *Front Immunol*. 2018;9:1931. doi: 10.3389/fimmu.2018.01931
  31. Nezenega ZS, Perimal-Lewis L, Maeder AJ. Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review. *Int J Environ Res Public Health* 2020;17(15):5626. doi: 10.3390/ijerph17155626
  32. Izudi J, Tamwesigire IK, Bajunirwe F. Sputum smear non-conversion among adult persons with bacteriologically confirmed pulmonary tuberculosis in rural eastern Uganda. *J Clin Tuberc Other Mycobact Dis* 2020;20:100168. doi: 10.1016/j.jctube.2020.100168
  33. Hermosilla S, You P, Aifah A, Abildayev T, Akilzhanova A, Kozhamkulov U, et al. Identifying risk factors associated with smear positivity of pulmonary tuberculosis in Kazakhstan. *PLoS One* 2017;12(3):e0172942. doi: 10.1371/journal.pone.0172942
  34. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2014. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK247419/>

**Table 1: Characteristics of study participants (N=213)**

Sl no.	Characteristics	Male (156)	Female (57)	Frequency n (%)	P value
<b>1</b>	<b>Age Categories, in years</b>				
	<60	123 (78.9)	40 (70.2)	163 (76.5)	
	≥60	33 (21.1)	17 (29.8)	50 (23.5)	0.186
<b>2</b>	<b>Marital status</b>				
	Currently married	144 (92.3)	51 (89.5)	195 (91.6)	
	Never married	12 (7.7)	6 (10.5)	18 (8.4)	0.510
<b>4</b>	<b>Smoking status**</b>				
	Non-Smoker	89 (57.1)	57 (100)	146 (68.5)	
	Smoker	66 (42.3)	0	66 (31.0)	
	No information	1 (0.6)	0	1 (0.5)	<0.001
<b>5</b>	<b>Alcohol use**</b>				
	Alcohol user	63 (40.4)	0	63 (29.6)	
	Non-drinker	92 (59.0)	57 (100)	149 (69.9)	
	No information	1 (0.6)	0	1 (0.5)	<0.001
<b>6</b>	<b>Diabetes Mellitus status</b>				
	Present	59 (37.9)	30 (53.6)	89 (41.8)	
	Absent	96 (61.5)	26 (44.2)	122 (57.3)	
	No information	1 (0.6)	1 (1.8)	2 (0.9)	0.044
<b>7</b>	<b>Hypertension</b>				
	Present	21 (13.5)	7 (12.5)	28 (13.2)	
	Absent	134 (85.9)	49 (85.7)	183 (85.9)	
	No information	1 (0.6)	1 (1.8)	2 (0.9)	0.843
<b>8</b>	<b>Other comorbidities</b>				

	Chronic heart disease	6 (3.84)	0	6 (2.8)	0.135
	Chronic obstructive pulmonary disease	5 (3.2)	1 (1.8)	6 (2.8)	0.578
	Asthma	5 (3.2)	1 (1.8)	6 (2.8)	0.578
	Hypothyroidism	2 (1.3)	2 (3.5)	4 (1.9)	0.283
	Cancer	0	2 (3.5)	2 (0.9)	0.18
	Stroke	1 (0.6)	0	1 (0.5)	0.547
	Chronic kidney disease	1 (0.6)	0	1 (0.5)	0.547
<b>9</b>	<b>Symptom history</b>				
	Cough	129 (82.7)	46 (80.7)	175 (82.2)	0.737
	Fever	21 (13.5)	7 (12.3)	28 (13.2)	0.821
	Loss of weight	5 (3.2)	2 (3.5)	7 (3.3)	0.912

\*\* Self-reported by participants


**Table 2: Relationship between sex, treatment compliance and sputum positivity**

		<b>Treatment compliance</b>		
<b>S.No</b>		<b>Yes</b>	<b>No</b>	<b>Odds ratio</b>
<b>1.</b>	<b>Sex</b>			
	Male	137 (87.8)	19 (12.2)	
	Female	43 (75.4)	14 (24.6)	2.348 (1.086-5.073)
<b>2.</b>		<b>Sputum positivity</b>		
	<b>Treatment compliance</b>	<b>Yes</b>	<b>No</b>	
	Compliance	13 (7.2)	167 (92.8)	
	Noncompliance	31 (93.9)	2 (6.1)	199.115 (42.804-926.244)

**Table 3: Results of Causal Mediation Analysis with Non-compliance to TB treatment Compliance as Mediator between Sex and Sputum Conversion in the Cohort of Newly Diagnosed Pulmonary TB patients at Chennai, South India**

Effect	Exposure	Odds Ratio (95% CI)*	P-value	Bias-corrected CIs
Marginal Total Effect (MTE) of Sex on Sputum positivity at the end of intensive phase	Females	6.77 (1.93-23.73)	0.003	1.83-29.00
	Males	Ref	-	-
Direct Effect of Sex on Sputum positivity at the end of intensive phase	Females	3.42 (1.15-10.22)	0.03	1.33-12.48
	Males	Ref	-	-
Indirect Effect of Sex on Sputum positivity via treatment compliance during intensive phase	Females	1.98 (1.08-3.62)	0.03	1.06-3.44
	Males	Ref	-	-
Effect of Sex on Non-compliance to TB treatment during the intensive phase	Females	2.35 (1.09-5.08)	0.03	[Not Applicable]
	Males	Ref	-	
Effect of Treatment compliance on Sputum positivity at the end of intensive phase	Non-compliant	199.11 (42.80-926.24)	<0.001	
	Compliant	Ref	-	





**Declaration of interests**

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

First Author Yuvaraj Krishnamoorthy is Associate Editor for Heliyon Journal